Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Arcoma AB's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Arcoma AB was 0.55. The lowest was 0.04. And the median was 0.30.
OSTO:ARCOMA's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Arcoma AB Debt-to-Equity Related Terms
Arcoma AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Arcoma AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Arcoma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Arcoma AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB (OSTO:ARCOMA) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Arcoma AB and its competitors. Over the past decade, Arcoma AB's Debt-to-Equity has ranged from 0.04 to 0.55. According to the industry distribution chart, Arcoma AB ranks #999999 out of 699 companies in the Medical Devices & Instruments industry.
Is Arcoma AB's Debt-to-Equity too high?
Arcoma AB's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.55. Based on the distribution chart, Arcoma AB ranks #999999 out of 699 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #999999 out of 699 companies for Debt-to-Equity. This places Arcoma AB in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Historically, Arcoma AB's own Debt-to-Equity has ranged from 0.04 to 0.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.90, compared to a current price of kr8.26 — trading 4.6% above its estimated fair value. The current Debt-to-Equity is 0.00. Arcoma AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.26 is trading 4.6% above its estimated GF Value™ of kr7.90.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
Debt-to-Equity: 0.00
GF Value™: kr7.90 vs. price of kr8.26 (4.6% above fair value)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
